Accelerating Translational Research: How Phage Display Technology Delivered High-Affinity Antibodies for Groundbreaking Applications

Phage Display: Redefining Antibody Discovery

At ProteoGenix, our goal is to provide more than a service, we aim to be an integral part of our clients’ success stories. By offering state-of-the-art antibody development technologies like phage display services and pairing them with expert scientific support, we enable researchers to achieve results that push the boundaries of discovery.

Professor Markella Ponticos selected us to develop specific monoclonal antibodies directed towards a mammalian cell surface protein via our phage display platform, which constitutes a revolutionary approach for antibody discovery and a gold standard to generate high affinity and highly specific antibodies.

Phage display offers unparalleled advantages over traditional methods like hybridoma as it allows for fast-track antibody discovery for even the most challenging targets such as cell surface proteins. ProteoGenix’s phage display service gives you access to:

• Vast library diversity: ProteoGenix’s extensive naïve and immune libraries, allow for the screening of billions of antibody variants from various species and formats (Fab, scFv, VHH) to identify the perfect candidate.
• Precision and efficiency: The technology accelerates the discovery of antibodies with optimal binding characteristics and functional activity.
• Customization for any application: Whether for research, diagnostics, or therapeutics, our phage display workflows are designed to meet the unique needs of each project.
• Transitional readiness: With seamless antibody humanization and optimization options, moving from research to clinical applications is faster than ever.

By leveraging phage display, ProteoGenix helped develop antibodies that met the highest standards of affinity and functionality, enabling Dr. Ponticos to confidently advance her work into preclinical studies.

Naïve Library Screening: Unlocking Infinite Possibilities in Antibody Discovery

One of the pivotal components of our phage display platform is naïve library screening, which allows for the rapid identification of high-affinity binders to virtually any target, including challenging antigens like cell surface proteins. ProteoGenix has developed a unique platform for generating diverse, high-quality naïve libraries containing billions of antibody variants in various formats, including scFv, Fab, and VHH, from multiple species.

Our selection of naïve libraries include:

Through a process known as panning antibodies with the best binding characteristics are enriched and validated. This robust method ensures the identification of antibodies with the highest potential for research, diagnostic, or therapeutic applications, offering an unparalleled advantage to researchers seeking precision and efficiency in their projects.

From Collaboration to Innovation: A Client’s Perspective

Dr. Ponticos graciously shared her thoughts on the collaboration, and her testimonial highlights the impact ProteoGenix had on her research journey:

“Our collaboration with ProteoGenix focused on the generation of specific monoclonal antibodies directed towards a mammalian cell surface protein. The antibodies developed exhibited very high affinity and performed in cell-based functional assays. This data propelled us towards advancing into pre-clinical in vivo and human work for the refinement and development of a potent biologic reagent. The invaluable technical and scientific guidance along with the expertise and support provided by our liaison at ProteoGenix played a pivotal role in the collaboration and advancing our translational research.” Markella Ponticos – Professor at University College London

Partnering for Breakthroughs in Antibody Development

Dr. Ponticos’ success story is a prime example of how ProteoGenix’s commitment to excellence in antibody discovery can enable researchers to overcome challenges and achieve groundbreaking results. From leveraging advanced technologies like phage display to providing tailored support through naïve library screening, we are dedicated to pushing the boundaries of what’s possible in translational research.

Whether you are at the early stages of discovery or advancing toward clinical applications, ProteoGenix is here to help. Let us be your trusted partner in turning bold ideas into meaningful innovations.

Explore our phage display services today and take the first step toward transforming your research into reality.